A prospective case-control study of 150 participants found circulating cell-free DNA distinguished ovarian cancer from benign ...
Testing to look for circulating tumor DNA in the blood is not new. These liquid biopsies – a fancy way of saying blood tests ...
New findings suggest that a blood test can detect circulating tumor DNA (ctDNA), potentially identifying signs of lung cancer ...
Dr. Rick Baehner, Abbott’s chief medical officer for precision oncology, spoke to MedTech Dive about how the new version of the Oncodetect test performs and the market it addresses.
Latent Class Analysis–Derived Classification and Cancer-Specific Death in Endometrial Carcinoma: A Population-Based Cohort Study Fifty-three of 58 patients (91.4%) from CO.28 had at least one sample ...
A retrospective single-center study found that tumor-informed circulating tumor DNA monitoring agreed with radiologic ...
Abbott will sell Freenome’s SimpleScreen CRC test in the U.S. alongside the Cologuard Plus stool-based test it gained in the $21 billion acquisition of Exact Sciences.
The growing role of Molecular Residual Disease (MRD) testing in cancer diagnosis and monitoring will be the focus of an ...
Foundation Medicine, Inc., a precision medicine company transforming lives in cancer care and beyond, today announced that ...
Despite advances in early-stage lung cancer treatment, a significant number of patients experience disease recurrence after surgery or initial therapy. A study has now demonstrated that a blood test ...
It may be possible to detect malignant lymphoma from a blood sample.Research findings to that effect were announced in ...
NeoCOAST-2 trial finds early ctDNA clearance in blood tests linked to improved lung cancer outcomes, potentially guiding ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results